Analyst Ratings (USA)
Today’s U.S. analyst updates suggest a selective and cautious market outlook, with optimism concentrated in cloud computing, AI infrastructure and networking, although target cuts across parts of enterprise software show continued valuation scrutiny. Financials face a more restrained outlook, with several bank and lending downgrades, while industrials, aerospace and chemicals saw numerous target reductions despite many favourable ratings remaining intact. Consumer sentiment is mixed: retail upgrades contrast with reductions in travel, restaurants and packaged foods. Energy remains selective, with stronger targets for refining and some producers offset by weaker oilfield-service forecasts. Utilities generally experienced lower targets, while healthcare and biotechnology showed a combination of positive coverage initiations and company-specific downgrades. Overall, the updates point to continued confidence in selected growth opportunities, accompanied by tighter expectations for valuations and earnings across much of the broader market.
U.S. Analyst Updates (238)
3M (MMM) — Deutsche Bank maintained its Hold rating and raised its price target to US$194.00 from US$192.00.
Accelerant (ARX) — TD Cowen downgraded the stock to Hold from Buy, lowering its price target to US$20.25 from US$30.00.
Accenture (ACN) — UBS reiterated its Buy rating.
Achieve Life Sciences (ACHV) — Stifel Nicolaus initiated coverage with a Buy rating and a US$18 price target.
Akamai Technologies (AKAM) — President Capital maintained its Buy rating and raised its price target to US$168.00 from US$150.00.
Aldeyra Therapeutics (ALDX) — H.C. Wainwright reiterated its Neutral rating with a US$2.00 price target.
Ally Financial (ALLY) — Wells Fargo downgraded the stock to Equal Weight from Overweight, lowering its price target to US$42.00 from US$55.00.
Alnylam Pharmaceuticals (ALNY) — Cantor Fitzgerald reiterated its Neutral rating.
Alnylam Pharmaceuticals (ALNY) — JPMorgan Chase maintained its Overweight rating and lowered its price target to US$369.00 from US$375.00.
Amazon.com (AMZN) — Rosenblatt Securities maintained its Buy rating and raised its price target to US$360.00 from US$335.00.
Ameren (AEE) — Mizuho maintained its Outperform rating and lowered its price target to US$113.00 from US$124.00.
American Electric Power (AEP) — Scotiabank maintained its Sector Perform rating and lowered its price target to US$131.00 from US$140.00.
American Express (AXP) — Citigroup maintained its Neutral rating and lowered its price target to US$340.00 from US$355.00.
American Tower (AMT) — Barclays maintained its Overweight rating and raised its price target to US$199.00 from US$198.00.
Amphenol (APH) — Wolfe Research initiated coverage with an Outperform rating and a US$105.00 price target.
Amplitude (AMPL) — Piper Sandler maintained its Overweight rating and raised its price target to US$18.00 from US$13.00.
AnaptysBio (ANAB) — JPMorgan Chase maintained its Overweight rating and lowered its price target to US$60.00 from US$70.00.
Annexon (ANNX) — JPMorgan Chase maintained its Overweight rating and raised its price target to US$15.00 from US$14.00.
Arcus Biosciences (RCUS) — Wedbush reiterated its Outperform rating with a US$43.00 price target.
Arista Networks (ANET) — Bernstein initiated coverage with an Outperform rating and a US$250.00 price target.
ASML (ASML) — Jefferies reiterated its Neutral rating.
ATI (ATI) — Wells Fargo maintained its Overweight rating and lowered its price target to US$240.00 from US$275.00.
Baker Hughes (BKR) — UBS maintained its Neutral rating and lowered its price target to US$69.00 from US$72.00.
Ballard Power Systems (BLDP) — UBS maintained its Neutral rating and lowered its price target to US$2.15 from US$6.50.
Banc of California (BANC) — Wells Fargo maintained its Overweight rating and lowered its price target to US$22.00 from US$23.00.
Bank of N.T. Butterfield & Son (NTB) — Wells Fargo maintained its Equal Weight rating and raised its price target to US$65.00 from US$61.00.
BankUnited (BKU) — Wells Fargo downgraded the stock to Equal Weight from Overweight, with a US$47 price target.
BioCryst Pharmaceuticals (BCRX) — JPMorgan Chase maintained its Neutral rating and raised its price target to US$13.00 from US$12.00.
Biomea Fusion (BMEA) — Citigroup reiterated its Market Outperform rating.
BlossomHill Therapeutics (BLSM) — H.C. Wainwright reiterated its Buy rating.
Boeing (BA) — Bernstein reiterated its Outperform rating.
Boeing (BA) — William Blair reiterated its Outperform rating.
BOK Financial (BOKF) — Wells Fargo downgraded the stock to Underweight from Equal Weight, with a US$135 price target.
Booking Holdings (BKNG) — Truist Securities maintained its Buy rating and lowered its price target to US$216.00 from US$242.00.
Braze (BRZE) — Cantor Fitzgerald reiterated its Overweight rating with a US$38.00 price target.
BWX Technologies (BWXT) — BofA Securities maintained its Buy rating and lowered its price target to US$210.00 from US$250.00.
BWX Technologies (BWXT) — BTIG Research reiterated its Buy rating with a US$235.00 price target.
BWX Technologies (BWXT) — Citigroup reiterated its Outperform rating.
BWX Technologies (BWXT) — Guggenheim reiterated its Buy rating with a US$192.00 price target.
BWX Technologies (BWXT) — Northland Securities maintained its Outperform rating and lowered its price target to US$220.00 from US$250.00.
Cactus (WHD) — Citigroup reiterated its Neutral rating.
CarMax (KMX) — Baird maintained its Outperform rating and raised its price target to US$70.00 from US$64.00.
CarMax (KMX) — Barclays set its price target to US$67.00.
CarMax (KMX) — BNP Paribas Exane maintained its Underperform rating and raised its price target to US$48.00 from US$33.00.
CarMax (KMX) — BofA Securities maintained its Underperform rating and raised its price target to US$50.00 from US$45.00.
CarMax (KMX) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$53.00 from US$47.00.
CarMax (KMX) — RBC Capital maintained its Sector Perform rating and raised its price target to US$56.00 from US$45.00.
CarMax (KMX) — Truist Securities maintained its Hold rating and raised its price target to US$60.00 from US$50.00.
CarMax (KMX) — UBS maintained its Neutral rating and raised its price target to US$62.00 from US$57.00.
Carnival (CCL) — Bernstein reiterated its Market Perform rating with a US$28.70 price target.
Carnival (CCL) — BNP Paribas Exane maintained its Outperform rating and lowered its price target to US$31.00 from US$33.00.
Carnival (CCL) — Mizuho maintained its Outperform rating and lowered its price target to US$38.00 from US$39.00.
Carnival (CCL) — Susquehanna maintained its Positive rating and lowered its price target to US$28.00 from US$33.00.
Carnival (CCL) — UBS reiterated its Buy rating with a US$36.00 price target.
Carpenter Technology (CRS) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$430.00 from US$540.00.
Carrier Global (CARR) — Deutsche Bank maintained its Hold rating and lowered its price target to US$64.00 from US$71.00.
Carrier Global (CARR) — Goldman Sachs maintained its Buy rating and lowered its price target to US$74.00 from US$85.00.
Cartesian Therapeutics (RNAC) — H.C. Wainwright reiterated its Buy rating with a US$25.00 price target.
Carvana (CVNA) — Oppenheimer maintained its Outperform rating and adjusted its price target to US$90.00 from US$450.00 following the stock split.
Cavco Industries (CVCO) — Oppenheimer initiated coverage with an Outperform rating and a US$720.00 price target.
Celanese (CE) — Citigroup maintained its Buy rating and lowered its price target to US$58.00 from US$60.00.
Celcuity (CELC) — Needham maintained its Buy rating and lowered its price target to US$134.00 from US$140.00.
Celestica (CLS) — Bernstein initiated coverage with an Outperform rating and a US$520.00 price target.
Certara (CERT) — UBS resumed coverage with a Neutral rating and a US$10.00 price target.
Champion Homes (SKY) — Oppenheimer initiated coverage with a Perform rating.
Charles River Laboratories International (CRL) — UBS resumed coverage with a Buy rating and a US$357.00 price target.
Chemours (CC) — Mizuho maintained its Outperform rating and lowered its price target to US$18.00 from US$20.00.
Chesapeake Utilities (CPK) — Wells Fargo maintained its Equal Weight rating and raised its price target to US$136.00 from US$134.00.
Ciena (CIEN) — Bernstein initiated coverage with an Outperform rating and a US$440.00 price target.
Cintas (CTAS) — Citigroup maintained its Sell rating and raised its price target to US$181.00 from US$180.00.
Cisco Systems (CSCO) — Bernstein initiated coverage with a Market Perform rating and a US$110.00 price target.
Coherent (COHR) — Bernstein initiated coverage with an Outperform rating and a US$350 price target.
Columbia Banking System (COLB) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$32.00 from US$34.00.
Concentrix (CNXC) — Canaccord Genuity reiterated its Buy rating with a US$45.00 price target.
Connect Biopharma (CNTB) — BTIG Research maintained its Buy rating and lowered its price target to US$5.00.
CoreWeave (CRWV) — William Blair initiated coverage with an Outperform rating.
Corning (GLW) — Bernstein initiated coverage with a Market Perform rating and a US$140.00 price target.
Crown Castle (CCI) — Barclays maintained its Overweight rating and raised its price target to US$86.00 from US$84.00.
Cummins (CMI) — UBS maintained its Buy rating and lowered its price target to US$741.00 from US$835.00.
Dakota Gold (DC) — H.C. Wainwright reiterated its Buy rating with a US$10.75 price target.
DBV Technologies (DBVT) — Citigroup reiterated its Market Outperform rating.
DICK’S Sporting Goods (DKS) — Guggenheim reiterated its Neutral rating.
DocGo (DCGO) — Needham reiterated its Buy rating.
DoorDash (DASH) — Citigroup reiterated its Market Outperform rating.
Dow (DOW) — Citigroup downgraded the stock to Neutral from Buy, with a US$30 price target.
Duke Energy (DUK) — Scotiabank lowered its price target to US$131.00 from US$146.00.
DuPont de Nemours (DD) — Goldman Sachs maintained its Neutral rating and lowered its price target to US$153.00 from US$159.00.
Dutch Bros (BROS) — Oppenheimer maintained its Outperform rating and lowered its price target to US$66.00 from US$82.00.
Dyne Therapeutics (DYN) — Cantor Fitzgerald reiterated its Buy rating.
Dyne Therapeutics (DYN) — Chardan Capital reiterated its Buy rating with a US$38.00 price target.
Dyne Therapeutics (DYN) — H.C. Wainwright maintained its Buy rating and lowered its price target to US$32.00 from US$50.00.
Dyne Therapeutics (DYN) — Jefferies reiterated its Buy rating with a US$50.00 price target.
Eastman Chemical (EMN) — Citigroup maintained its Buy rating and lowered its price target to US$76.00 from US$81.00.
Elanco Animal Health (ELAN) — KeyBanc Capital Markets reiterated its Overweight rating.
Emerson Electric (EMR) — Deutsche Bank maintained its Hold rating and raised its price target to US$174.00 from US$169.00.
Equifax (EFX) — BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$160.00 from US$179.00.
Expedia Group (EXPE) — Truist Securities maintained its Hold rating and lowered its price target to US$288.00 from US$309.00.
Expeditors International of Washington (EXPD) — BNP Paribas Exane initiated coverage with a Neutral rating and a US$180.00 price target.
Fair Isaac (FICO) — Barclays maintained its Overweight rating and lowered its price target to US$935.00 from US$1,700.00.
Fair Isaac (FICO) — BMO Capital Markets maintained its Outperform rating and lowered its price target to US$1,150.00 from US$1,550.00.
Fair Isaac (FICO) — BofA Securities downgraded the stock to Neutral from Buy, lowering its price target to US$700.00 from US$1,400.00.
Fair Isaac (FICO) — Susquehanna set its price target to US$700.00.
Fair Isaac (FICO) — Wells Fargo maintained its Overweight rating and lowered its price target to US$950.00 from US$1,350.00.
FedEx (FDX) — BNP Paribas Exane maintained its Neutral rating and raised its price target to US$300.00 from US$269.80.
Ferrari (RACE) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$456.00 from US$460.00.
First Hawaiian (FHB) — Wells Fargo maintained its Underweight rating and lowered its price target to US$26.00 from US$28.00.
First Horizon (FHN) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$25.00 from US$28.00.
First Solar (FSLR) — Piper Sandler maintained its Overweight rating and lowered its price target to US$251.00 from US$260.00.
First Tracks Biotherapeutics (TRAX) — Canaccord Genuity initiated coverage with a Buy rating and a US$50.00 price target.
Flywire (FLYW) — RBC Capital reiterated its Outperform rating with a US$25.00 price target.
Forbright (FRBT) — Wells Fargo maintained its Overweight rating and lowered its price target to US$21.00 from US$22.00.
FormFactor (FORM) — Deutsche Bank initiated coverage with a Buy rating and a US$200.00 price target.
Fortrea (FTRE) — UBS initiated coverage with a Neutral rating and a US$22.00 price target.
GE Aerospace (GE) — Wells Fargo maintained its Overweight rating and lowered its price target to US$380.00 from US$390.00.
Generac (GNRC) — Citigroup reiterated its Neutral rating.
Generac (GNRC) — Stifel Nicolaus maintained its Buy rating and raised its price target to US$290.00 from US$285.00.
Global Business Travel Group (GBTG) — BTIG Research reiterated its Neutral rating.
Graphic Packaging (GPK) — RBC Capital maintained its Sector Perform rating and lowered its price target to US$10.00 from US$11.00.
Grocery Outlet (GO) — BofA Securities upgraded the stock to Buy from Neutral, raising its price target to US$15.00 from US$12.50.
H2O America (HTO) — Barclays maintained its Overweight rating and lowered its price target to US$66.00 from US$67.00.
Hawaiian Electric Industries (HE) — Barclays maintained its Equal Weight rating and lowered its price target to US$9.00 from US$12.00.
HawkEye 360 (HAWK) — RBC Capital maintained its Outperform rating and lowered its price target to US$28.00 from US$33.00.
HEICO (HEI) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$335.00 from US$350.00.
Hexcel (HXL) — Wells Fargo maintained its Overweight rating and lowered its price target to US$105.00 from US$120.00.
Hinge Health (HNGE) — Needham maintained its Buy rating and raised its price target to US$115.00 from US$97.00.
Howmet Aerospace (HWM) — Citigroup reiterated its Buy rating.
Howmet Aerospace (HWM) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$255.00 from US$315.00.
Huntsman (HUN) — Citigroup maintained its Neutral rating and lowered its price target to US$9.00 from US$11.00.
ICON plc (ICLR) — UBS resumed coverage with a Neutral rating and a US$195.00 price target.
Illinois Tool Works (ITW) — Deutsche Bank maintained its Hold rating and lowered its price target to US$281.00 from US$287.00.
Immix Biopharma (IMMX) — Citigroup reiterated its Market Outperform rating.
Innio (INIO) — Goldman Sachs set its price target to US$35.00.
Insmed (INSM) — Barclays maintained its Overweight rating and lowered its price target to US$207.00 from US$237.00.
Iovance Biotherapeutics (IOVA) — Wells Fargo maintained its Overweight rating and raised its price target to US$18.00 from US$14.00.
IperionX (IPX) — B. Riley Securities maintained its Buy rating and lowered its price target to US$34.00 from US$52.00.
IQVIA (IQV) — UBS resumed coverage with a Buy rating and a US$345.00 price target.
Jack Henry & Associates (JKHY) — Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$158.00 from US$170.00.
Jack Henry & Associates (JKHY) — RBC Capital reiterated its Outperform rating with a US$178.00 price target.
Jazz Pharmaceuticals (JAZZ) — Citigroup initiated coverage with a Buy rating and a US$325.00 price target.
John B. Sanfilippo & Son (JBSS) — BWS Financial reiterated its Buy rating with a US$109.00 price target.
Johnson Controls International (JCI) — Deutsche Bank maintained its Buy rating and lowered its price target to US$178.00 from US$180.00.
Johnson Controls International (JCI) — Goldman Sachs maintained its Buy rating and raised its price target to US$191.00 from US$186.00.
Kiniksa Pharmaceuticals International (KNSA) — Wells Fargo initiated coverage with an Overweight rating and a US$87.00 price target.
Kodiak Sciences (KOD) — Goldman Sachs reiterated its Neutral rating with a US$103.00 price target.
Lamb Weston (LW) — JPMorgan Chase maintained its Neutral rating and lowered its price target to US$46.00 from US$52.00.
Levi Strauss & Co. (LEVI) — BTIG Research reiterated its Buy rating with a US$27.00 price target.
Liberty Energy (LBRT) — UBS maintained its Buy rating and lowered its price target to US$31.00 from US$35.00.
Lumentum (LITE) — Bernstein initiated coverage with an Outperform rating and a US$1,220.00 price target.
LyondellBasell Industries (LYB) — Citigroup downgraded the stock to Neutral from Buy, lowering its price target to US$63.00 from US$72.00.
Medpace (MEDP) — UBS resumed coverage with a Neutral rating and a US$673.00 price target.
Medtronic (MDT) — TD Cowen reiterated its Buy rating with a US$110.00 price target.
Microsoft (MSFT) — Piper Sandler maintained its Overweight rating and raised its price target to US$610.00 from US$550.00.
Mobileye Global (MBLY) — Barclays downgraded the stock to Equal Weight from Overweight, lowering its price target to US$9.00 from US$14.00.
Moderna (MRNA) — Citigroup downgraded the stock to Sell from Neutral, raising its price target to US$80.00 from US$60.00.
MongoDB (MDB) — BMO Capital Markets maintained its Outperform rating and lowered its price target to US$420.00 from US$450.00.
MongoDB (MDB) — Citizens JMP reiterated its Market Outperform rating with a US$519.00 price target.
MongoDB (MDB) — Morgan Stanley reiterated its Overweight rating.
MongoDB (MDB) — Needham reiterated its Buy rating with a US$430.00 price target.
MongoDB (MDB) — Piper Sandler reiterated its Overweight rating with a US$470.00 price target.
MongoDB (MDB) — RBC Capital reiterated its Outperform rating with a US$465.00 price target.
MongoDB (MDB) — Stephens maintained its Equal Weight rating and lowered its price target to US$372.00 from US$398.00.
MongoDB (MDB) — Stifel Nicolaus maintained its Buy rating and lowered its price target to US$385.00 from US$465.00.
MongoDB (MDB) — UBS maintained its Neutral rating and lowered its price target to US$375.00 from US$410.00.
Morgan Stanley (MS) — Citigroup reiterated its Neutral rating.
National Energy Services Reunited (NESR) — Capital One initiated coverage with an Overweight rating and a US$44.00 price target.
National Energy Services Reunited (NESR) — National Bank Financial set its price target to US$44.00.
Nebius Group (NBIS) — William Blair initiated coverage with an Outperform rating.
Neogen (NEOG) — Guggenheim maintained its Buy rating and raised its price target to US$14.00 from US$12.00.
NetApp (NTAP) — BofA Securities maintained its Neutral rating and raised its price target to US$220.00 from US$200.00.
NextEra Energy (NEE) — Scotiabank maintained its Outperform rating and lowered its price target to US$99.00 from US$110.00.
Nextpower (NXT) — Piper Sandler maintained its Overweight rating and lowered its price target to US$110.00 from US$116.00.
NICE (NICE) — Oppenheimer upgraded the stock to Outperform from Perform, with a US$150.00 price target.
Norfolk Southern (NSC) — Evercore raised its price target to US$360.00 from US$358.00.
Nuvation Bio (NUVB) — Citigroup initiated coverage with a Buy rating and a US$12.00 price target.
Olin (OLN) — Citigroup maintained its Neutral rating and lowered its price target to US$17.00 from US$19.00.
Olin (OLN) — Goldman Sachs set its price target to US$18.00.
Ovintiv (OVV) — National Bank Financial maintained its Outperform rating and raised its price target to US$91.00 from US$83.00.
Pasqal Holding (PSQL) — Needham initiated coverage with a Buy rating and a US$16.00 price target.
Pasqal Holding (PSQL) — Williams Trading set its price target to US$16.00.
Paysign (PAYS) — DA Davidson maintained its Buy rating and raised its price target to US$15.00 from US$12.00.
PepsiCo (PEP) — Barclays lowered its price target to US$133.00 from US$142.00.
PepsiCo (PEP) — Evercore lowered its price target to US$135.00 from US$150.00.
Perpetua Resources (PPTA) — H.C. Wainwright reiterated its Buy rating with a US$43.50 price target.
Phillips 66 (PSX) — Goldman Sachs maintained its Neutral rating and raised its price target to US$274.00 from US$245.00.
Phillips 66 (PSX) — TD Cowen maintained its Buy rating and raised its price target to US$295.00 from US$255.00.
Pinnacle Financial Partners (PNFP) — Wells Fargo upgraded the stock to Overweight from Equal Weight, with a US$118.00 price target.
Portland General Electric (POR) — BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$47.00 from US$52.00.
PPG Industries (PPG) — Citigroup maintained its Neutral rating and lowered its price target to US$118.00 from US$121.00.
Procter & Gamble (PG) — TD Cowen reiterated its Hold rating with a US$150.00 price target.
Progyny (PGNY) — Wells Fargo initiated coverage with an Overweight rating and a US$37.00 price target.
QumulusAI (QMLS) — Chardan Capital reiterated its Buy rating with a US$23.00 price target.
Regal Rexnord (RRX) — Goldman Sachs set its price target to US$216.00.
Rexford Industrial Realty (REXR) — Cantor Fitzgerald reiterated its Overweight rating.
Rezolute (RZLT) — Lake Street Capital initiated coverage with a Buy rating and a US$9.00 price target.
Robinhood Markets (HOOD) — Morgan Stanley reiterated its Overweight rating with a US$150.00 price target.
Rockwell Automation (ROK) — Deutsche Bank maintained its Hold rating and raised its price target to US$500.00 from US$469.00.
Rockwell Automation (ROK) — Goldman Sachs maintained its Neutral rating and lowered its price target to US$485.00 from US$510.00.
Sable Offshore (SOC) — Roth Capital maintained its Buy rating and lowered its price target to US$10.00 from US$11.00.
Sarepta Therapeutics (SRPT) — JPMorgan Chase maintained its Neutral rating and lowered its price target to US$20.00 from US$23.00.
SBA Communications (SBAC) — Barclays maintained its Overweight rating and lowered its price target to US$207.00 from US$208.00.
Select Water Solutions (WTTR) — BofA Securities maintained its Buy rating and raised its price target to US$28.00 from US$24.00.
Select Water Solutions (WTTR) — UBS reiterated its Buy rating with a US$28.00 price target.
Sensient Technologies (SXT) — UBS maintained its Buy rating and raised its price target to US$157.00 from US$155.00.
Smithfield Foods (SFD) — Stephens initiated coverage with an Equal Weight rating and a US$22.00 price target.
Solstice Advanced Materials (SOLS) — RBC Capital reiterated its Outperform rating with a US$82.00 price target.
SoundThinking (SSTI) — Citigroup reiterated its Market Perform rating.
SoundThinking (SSTI) — Jefferies set its price target to US$9.00.
SoundThinking (SSTI) — Roth Capital downgraded the stock to Neutral from Buy, with a US$9.00 price target.
SpaceX (SPCX) — Needham reiterated its Buy rating.
Sterling Infrastructure (STRL) — Cantor Fitzgerald reiterated its Overweight rating with a US$742.00 price target.
Stryker (SYK) — Stifel Nicolaus maintained its Buy rating and lowered its price target to US$330.00 from US$360.00.
Summit Therapeutics (SMMT) — H.C. Wainwright reiterated its Neutral rating.
Surgery Partners (SGRY) — RBC Capital reiterated its Outperform rating with a US$19.00 price target.
Sutro Biopharma (STRO) — Wells Fargo resumed coverage with an Overweight rating and a US$49.00 price target.
Tandem Diabetes Care (TNDM) — Citigroup maintained its Neutral rating and lowered its price target to US$20.00 from US$24.00.
Target (TGT) — HSBC Securities upgraded the stock to Buy from Hold, with a US$190 price target.
Tectonic Therapeutic (TECX) — Oppenheimer reiterated its Outperform rating with a US$80.00 price target.
Tectonic Therapeutic (TECX) — TD Cowen reiterated its Buy rating.
TFI International (TFII) — RBC Capital maintained its Outperform rating and lowered its price target to US$144.00 from US$171.00.
Third Coast Bancshares (TCBX) — Brean Capital initiated coverage with a Neutral rating and a US$47.00 price target.
Transdigm Group (TDG) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$1,210.00 from US$1,450.00.
Tronox (TROX) — Mizuho maintained its Underperform rating and lowered its price target to US$4.50 from US$5.50.
Uber Technologies (UBER) — Bernstein reiterated its Outperform rating.
UFP Industries (UFPI) — Oppenheimer initiated coverage with a Perform rating.
uniQure (QURE) — Goldman Sachs maintained its Neutral rating and lowered its price target to US$31.00 from US$46.00.
Vail Resorts (MTN) — Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$142.00 from US$147.00.
Vale (VALE) — JPMorgan Chase maintained its Overweight rating and raised its price target to US$22.00 from US$21.00.
Viking (VIK) — UBS reiterated its Buy rating.
Wayfair (W) — Piper Sandler reiterated its Overweight rating with a US$133.00 price target.
Westlake (WLK) — Citigroup maintained its Neutral rating and lowered its price target to US$67.00 from US$85.00.
Woodward (WWD) — Wells Fargo maintained its Overweight rating and lowered its price target to US$430.00 from US$440.00.
Workday (WDAY) — Cantor Fitzgerald reiterated its Overweight rating.
Xencor (XNCR) — Wells Fargo resumed coverage with an Overweight rating and a US$55.00 price target.
Zenas BioPharma (ZBIO) — Citigroup reiterated its Buy rating.
Zenas BioPharma (ZBIO) — Guggenheim reiterated its Buy rating with a US$55.00 price target.
Zenas BioPharma (ZBIO) — H.C. Wainwright reiterated its Buy rating with a US$44.00 price target.
Zenas BioPharma (ZBIO) — Wedbush reiterated its Outperform rating with a US$45.00 price target.
Zentalis Pharmaceuticals (ZNTL) — Wells Fargo resumed coverage with an Equal Weight rating and a US$5.00 price target.
More Ratings:
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.